Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 2
1970 2
1978 1
1980 2
1981 1
2001 1
2002 1
2011 1
2015 1
2016 1
2019 1
2020 1
2021 3
2022 3
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study.
Brooks KM, Kiser JJ, Ziemba L, Ward S, Rani Y, Cressey TR, Masheto GR, Cassim H, Deville JG, Ponatshego PL, Patel F, Aurpibul L, Barnabas SL, Mustich I, Coletti A, Heckman B, Krotje C, Lojacono M, Yin DE, Townley E, Moye J, Majji S, Acosta EP, Ryan K, Chandasana H, Brothers CH, Buchanan AM, Rabie H, Flynn PM; IMPAACT 2019 Study Team. Brooks KM, et al. Among authors: townley e. Lancet HIV. 2023 Aug;10(8):e506-e517. doi: 10.1016/S2352-3018(23)00107-8. Lancet HIV. 2023. PMID: 37541705 Clinical Trial.
Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age.
MacBrayne CE, Rutstein RM, Wiznia AA, Graham B, Alvero CG, Fairlie L, Lypen K, George KH, Townley E, Moye J Jr, Costello DG, Reding CA, Barroso Hofer C, Crauwels HM, Woot de Trixhe X, Tambuyzer L, Vanveggel S, Opsomer M, Kiser JJ; and the IMPAACT P1090 Protocol Team. MacBrayne CE, et al. Among authors: townley e. AIDS. 2021 Jul 15;35(9):1413-1421. doi: 10.1097/QAD.0000000000002902. AIDS. 2021. PMID: 33831904 Free PMC article.
Forty-Eight Week Outcomes of a Site-Randomized Trial of Combined Cognitive Behavioral Therapy and Medication Management Algorithm for Treatment of Depression Among Youth With HIV in the United States.
Brown LK, Baltrusaitis K, Kennard BD, Emslie GJ, Chernoff M, Buisson S, Lypen K, Whiteley LB, Traite S, Krotje C, Knowles K, Townley E, Deville J, Wilkins M, Reirden D, Paul M, Beneri C, Shapiro DE; IMPAACT 2002 Team. Brown LK, et al. Among authors: townley e. J Acquir Immune Defic Syndr. 2022 Nov 1;91(3):296-304. doi: 10.1097/QAI.0000000000003058. Epub 2022 Jul 20. J Acquir Immune Defic Syndr. 2022. PMID: 35839439 Free PMC article. Clinical Trial.
Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents.
Chandasana H, Thapar M, Hayes S, Baker M, Gibb DM, Turkova A, Ford D, Ruel T, Wiznia A, Fairlie L, Bwakura-Dangarembizi M, Mujuru H, Alvero C, Farhad M, Hazra R, Townley E, Buchanan A, Bollen P, Waalewijn H, Colbers A, Burger D, Acosta EP, Singh R; IMPAACT P1093, ODYSSEY (PENTA 20) Study Teams. Chandasana H, et al. Among authors: townley e. Clin Pharmacokinet. 2023 Oct;62(10):1445-1459. doi: 10.1007/s40262-023-01289-5. Epub 2023 Aug 21. Clin Pharmacokinet. 2023. PMID: 37603217 Free PMC article.
Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women.
Mathad JS, Savic R, Britto P, Jayachandran P, Wiesner L, Montepiedra G, Norman J, Zhang N, Townley E, Chakhtoura N, Bradford S, Patil S, Popson S, Chipato T, Rouzier V, Langat D, Chalermchockcharoentkit A, Kamthunzi P, Gupta A, Dooley KE. Mathad JS, et al. Among authors: townley e. Clin Infect Dis. 2022 May 3;74(9):1604-1613. doi: 10.1093/cid/ciab665. Clin Infect Dis. 2022. PMID: 34323955 Free PMC article. Clinical Trial.
Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial.
Ruel TD, Acosta EP, Liu JP, Gray KP, George K, Montañez N, Popson S, Buchanan AM, Bartlett M, Dayton D, Anthony P, Brothers C, Vavro C, Singh R, Koech L, Vhembo T, Mmbaga BT, Pinto JA, Dobbels EFM, Archary M, Chokephaibulkit K, Ounchanum P, Deville JG, Hazra R, Townley E, Wiznia A; IMPAACT P1093 team. Ruel TD, et al. Among authors: townley e. Lancet HIV. 2022 May;9(5):e332-e340. doi: 10.1016/S2352-3018(22)00044-3. Lancet HIV. 2022. PMID: 35489377 Free PMC article. Clinical Trial.
Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis.
Krogstad P, Samson P, Acosta EP, Moye J, Townley E, Bradford S, Brown E, Denson K, Graham B, Hovind L, Sise T, Teppler H, Mathiba SR, Fairlie L, Winckler JL, Slade G, Meyers T; International Maternal Pediatric Adolescent AIDS Clinical Trials Network P1101 Team. Krogstad P, et al. Among authors: townley e. J Pediatric Infect Dis Soc. 2021 Mar 26;10(2):201-204. doi: 10.1093/jpids/piaa039. J Pediatric Infect Dis Soc. 2021. PMID: 32448902 Free PMC article. Clinical Trial.
Site-Randomized Controlled Trial of a Combined Cognitive Behavioral Therapy and a Medication Management Algorithm for Treatment of Depression Among Youth Living With HIV in the United States.
Brown LK, Chernoff M, Kennard BD, Emslie GJ, Lypen K, Buisson S, Weinberg A, Whiteley LB, Traite S, Krotje C, Harriff L, Townley E, Bunch A, Purswani M, Shaw R, Spector SA, Agwu A, Shapiro DE; IMPAACT 2002 team. Brown LK, et al. Among authors: townley e. J Acquir Immune Defic Syndr. 2021 Dec 15;88(5):497-505. doi: 10.1097/QAI.0000000000002790. J Acquir Immune Defic Syndr. 2021. PMID: 34483297 Free PMC article. Clinical Trial.
Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014.
Melvin AJ, Yee KL, Gray KP, Yedla M, Wan H, Tobin NH, Teppler H, Campbell H, McCarthy K, Scheckter R, Aurpibul L, Ounchanum P, Rungmaitree S, Cassim H, McFarland E, Flynn P, Cooper E, Krotje C, Townley E, Moye J, Best BM; IMPAACT 2014 study team. Melvin AJ, et al. Among authors: townley e. J Acquir Immune Defic Syndr. 2023 Feb 1;92(2):153-161. doi: 10.1097/QAI.0000000000003116. J Acquir Immune Defic Syndr. 2023. PMID: 36215957 Free PMC article.
Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis.
Meyers T, Samson P, Acosta EP, Moye J, Townley E, Bradford S, Marillo L, Denson K, Hovind L, Sise T, Teppler H, Mathiba SR, Masenya M, Hesseling A, Cotton MF, Krogstad P; IMPAACT P1101 Team. Meyers T, et al. Among authors: townley e. AIDS. 2019 Nov 15;33(14):2197-2203. doi: 10.1097/QAD.0000000000002369. AIDS. 2019. PMID: 31689263 Free PMC article. Clinical Trial.
28 results